ELVN
Price
$20.28
Change
-$0.67 (-3.20%)
Updated
Sep 4, 02:01 PM (EDT)
Capitalization
1.24B
63 days until earnings call
LABFF
Price
$90.61
Change
+$4.56 (+5.30%)
Updated
Jul 1 closing price
Capitalization
3.46B
Interact to see
Advertisement

ELVN vs LABFF

Header iconELVN vs LABFF Comparison
Open Charts ELVN vs LABFFBanner chart's image
Enliven Therapeutics
Price$20.28
Change-$0.67 (-3.20%)
Volume$200
Capitalization1.24B
LABORATORIOS FARMACEUTICOS ROVI SA
Price$90.61
Change+$4.56 (+5.30%)
Volume$100
Capitalization3.46B
ELVN vs LABFF Comparison Chart in %
Loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVN vs. LABFF commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a StrongBuy and LABFF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ELVN: $20.95 vs. LABFF: $90.61)
Brand notoriety: ELVN and LABFF are both not notable
ELVN represents the Biotechnology, while LABFF is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELVN: 89% vs. LABFF: 100%
Market capitalization -- ELVN: $1.24B vs. LABFF: $3.46B
ELVN [@Biotechnology] is valued at $1.24B. LABFF’s [@Pharmaceuticals: Generic] market capitalization is $3.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.55B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 1 FA rating(s) are green whileLABFF’s FA Score has 2 green FA rating(s).

  • ELVN’s FA Score: 1 green, 4 red.
  • LABFF’s FA Score: 2 green, 3 red.
According to our system of comparison, LABFF is a better buy in the long-term than ELVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 5 TA indicator(s) are bullish.

  • ELVN’s TA Score: 5 bullish, 4 bearish.

Price Growth

ELVN (@Biotechnology) experienced а +1.31% price change this week, while LABFF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.71%. For the same industry, the average monthly price growth was +5.90%, and the average quarterly price growth was +27.78%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.25%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was +82.50%.

Reported Earning Dates

ELVN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (-0.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LABFF($3.46B) has a higher market cap than ELVN($1.24B). LABFF YTD gains are higher at: 0.000 vs. ELVN (-6.889). LABFF has higher annual earnings (EBITDA): 203M vs. ELVN (-113.93M). ELVN has more cash in the bank: 491M vs. LABFF (47.6M). ELVN has less debt than LABFF: ELVN (580K) vs LABFF (129M). LABFF has higher revenues than ELVN: LABFF (749M) vs ELVN (0).
ELVNLABFFELVN / LABFF
Capitalization1.24B3.46B36%
EBITDA-113.93M203M-56%
Gain YTD-6.8890.000-
P/E RatioN/A28.85-
Revenue0749M-
Total Cash491M47.6M1,032%
Total Debt580K129M0%
TECHNICAL ANALYSIS
Technical Analysis
ELVNLABFF
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
14%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
14%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGFFX83.370.32
+0.39%
American Funds Growth Fund of Amer 529F
GISOX17.650.03
+0.17%
Grandeur Peak Intl Stalwarts Inv
MKSPX30.510.01
+0.03%
BlackRock Advantage SMID Cap K
FTGRX28.67N/A
N/A
Fidelity Advisor Mega Cap Stock M
PMYRX13.03-0.02
-0.15%
Victory Pioneer Equ Premium Income Y

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with CRNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
+0.29%
CRNX - ELVN
51%
Loosely correlated
+4.05%
SYRE - ELVN
51%
Loosely correlated
+1.08%
XNCR - ELVN
49%
Loosely correlated
-2.57%
ERAS - ELVN
48%
Loosely correlated
-10.63%
DNLI - ELVN
48%
Loosely correlated
-0.91%
More

LABFF and

Correlation & Price change

A.I.dvisor indicates that over the last year, LABFF has been closely correlated with XTLB. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if LABFF jumps, then XTLB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LABFF
1D Price
Change %
LABFF100%
N/A
XTLB - LABFF
70%
Closely correlated
-0.84%
ELVN - LABFF
39%
Loosely correlated
+0.29%
CRNX - LABFF
35%
Loosely correlated
+4.05%
TOVX - LABFF
27%
Poorly correlated
+5.44%
ATOS - LABFF
26%
Poorly correlated
+0.56%
More